Utility of AgNor, immunocytochemistry for CEA and tumor markers for diagnosis in serous fluids

Objective: The evaluation of serous fluids stained by morphological methods lacks, in many cases, the necessary accuracy to obtain the correct diagnostics. The objective of this work was to establish the value of complementary tools for the improvement of diagnosis in serous effusions. Methods: Fifty-six serous effusions were processed for morphological staining, immunocytochemistry of carcinoembryonic antigen (CEA), AgNOR counting and electrochemiluminescense immunoassay for tumor markers (TM): CEA, Ca125 and CYFRA 21-1. TM assays were also performed in sera from the same patients. The Sensitivity (Se) and Specificity (Sp) were evaluated for all the methods. Results: Cytology: Se 73 per cent, Sp 100 per cent, CEA by immunocytochemistry: Se 96 per cent, Sp 75 per cent, AgNOR:Se 86 per cent, Sp100 per cent, TM: a) in fluids: CEA, Ca125 and CYFRA 21-1, Se: 29 per cent, 66 per cent and 64 per cent respectively and Sp: 100 por cento, 87 por cento and 100 por cento respectively. b) in sera: CEA, Ca125 and CYFRA 21-1: Se: 27 per cent, 77 per cent and 47 per cent respectively and Sp: 100 per cent, 25 per cent and 75 per cent respectively. CEA (in cells) + TM (fluids): Se 100 per cent and Sp 75 per cent AgNOR + TM (fluids): Se 95 per cent and Sp 87 per cent TM Panel (CEA+Ca125+CYFRA 21-1): a) in fluids: Se 81 per cent and Sp 87 per cent b) in sera: Se 86 per cent and Sp 12 per cent Conclusion: AgNOR assay and immunocytochemistry for CEA were useful as complementary tools in the diagnosis using effusions, raising the Sensitivity of the Cytology from 73 per cent to 86 per cent and 96 per cent respectively. Sensitivity increased with the assays for a panel of TM in fluids, but the high costof these methods does not justify their use for non-conclusive smears.

Utilidad de los marcadores tumorales en líquidos de punción pleural / Usefulness of tumor markers in pleural fluids

El diagnóstico de la neoplasia pleural se basa en la demostración de células neoplásicas en fluido pleural (FP) o en biopsias de pleura. Sin embargo, aún en casos de malignidad hay un elevado porcentaje de informes falsos negativos (30-60%). Los FP neoplásicos presentan valores detectables de marcadores tumorales (MT) producidos por las células neoplásicas de la pleura. El objetivo de este trabajo ha sido evaluar la utilidad diagnóstica de algunos marcadores tumorales, de uso corriente en el laboratorio, en los fluidos de punción pleural. En 20 de ellos se analizaron: Antígeno cárcinoembrionario (CEA), fragmentos de la citoqueratina 19 (CYFRA 21-1) y Antígeno CA 125. Se efectuó el estudio fisicoquímico, recuento celular y examen citológico (Papanicolaou). En algunos casos se realizó diagnóstico anátomo-patológico. Los MT se dosaron por inmunoensayo de electroquimioluminiscencia. La comparación se efectuó por Kruskal-Wallis. Las muestras fueron clasificadas en 4 grupos y se determinó en cada uno mediana y rango para CEA (ng/mL), CYFRA (ng/mL) y CA 125 (UI/mL), respectivamente: 1) Citología positiva con diagnóstico previo de cáncer de pulmón (n: 5) 112 (2,3-1.610), 134,4 (45,8-600), 1.048 (498-2999); 2) Citología positiva con diagnóstico previo de cáncer de otro origen (n: 4) 15,28 (1,1-93,80), 108,1 (7,42-497,2), 1.827 (1.103-14.130); 3) Citología negativa con diagnóstico incierto (n: 4) 1,89 (0,91-2,96), 17,1 (1,5-29,6), 578,2 (27,8-12); 4) Citología no concluyente con diagnóstico incierto (n: 7) 31,8 (1,28-370,2), 96,3 (23,8-860), 585 (94,4-4.584). Se observó diferencia significativa entre los grupos. La combinación de citología y MT aumentó el diagnóstico de neoplasia pleural en 25%. Los resultados preliminares permiten concluir que un panel de marcadores tumorales en FP, sumado a los estudios tradicionales, representa una ayuda diagnóstica.

The diagnosis of pleural cancer is supported by the demonstration of neoplastic cells in pleural fluid or in pleural biopsies. However, even in malignancy there are a great number of false negatives results (30-60%). Tumor fluids. To establish the value of different tumor markers, frequently used in clinical laboratories, in the diagnosis of pleural fluids. 20 pleural fluids were processed for physical and chemical study, cellular counting, morphological examination (Papanicolaou stain) and electrochemiluminescense immunoassay for carcinoembryonic antigen (CEA), CYFRA 21-1 and CA 125. The results were analysed by Kruskal-Wallis. In some cases, biopsies were performed. The samples were classified in four groups, and the median and rank were calculated in each case (CEA, CYFRA and CA 125). 1) Positive cytology with previous diagnosis of lung cancer (n: 5) 112 (2.3-1610), 134.4 (45.8-600), 1048 (498-2999) 2) Positive cytology with previous diagnosis of not-lung cancer(n: 4) 15.28 (1.1-93.80), 108.1 (7.42- 497.2),1827 (1103-14130), 3) Negative cytology with uncertain diagnosis (n: 4)1.89 (0.91- 2.96), 17.1 (1.5-29.6), 578.2 (27.8-12, 4) Inconclusive cytology with uncertain diagnosis (n: 7) 31.8 (1.28-370.2), 96.3 (23.8-860), 585 (94.4 -4584). There were stastistic differences among the four groups. Joining the cytology to the assays for tumor markers raised sensitivity by 25%. The assay for tumor markers can be a complementary tool in the diagnosis of effusions.